Satya Yendluri
Overview
Explore the profile of Satya Yendluri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lapointe G, Skepper C, Holder L, Armstrong D, Bellamacina C, Blais J, et al.
J Med Chem
. 2021 Apr;
64(9):6329-6357.
PMID: 33929852
Herein, we describe the discovery and optimization of a novel series that inhibits bacterial DNA gyrase and topoisomerase IV binding to, and stabilization of, DNA cleavage complexes. Optimization of this...
2.
Jensen K, Tadin-Strapps M, Wang S, Hubert J, Kan Y, Ma Y, et al.
J Lipid Res
. 2016 Oct;
57(12):2150-2162.
PMID: 27707816
SREBP cleavage-activating protein (SCAP) is a key protein in the regulation of lipid metabolism and a potential target for treatment of dyslipidemia. SCAP is required for activation of the transcription...
3.
Fenaux M, Lin X, Yokokawa F, Sweeney Z, Saunders O, Xie L, et al.
Antimicrob Agents Chemother
. 2016 Sep;
60(12):7077-7085.
PMID: 27645237
Nucleoside or nucleotide inhibitors are a highly successful class of antivirals due to selectivity, potency, broad coverage, and high barrier to resistance. Nucleosides are the backbone of combination treatments for...
4.
Tadin-Strapps M, Robinson M, Le Voci L, Andrews L, Yendluri S, Williams S, et al.
J Cardiovasc Transl Res
. 2015 Jan;
8(1):44-53.
PMID: 25604958
Lipoprotein(a) [Lp(a)] has recently been recognized as an independent risk factor for coronary heart disease. While plasma Lp(a) levels are correlated with cardiovascular risk, the mechanism by which this particle...
5.
Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, et al.
J Virol
. 2009 Feb;
83(8):3450-62.
PMID: 19193803
Oncolytic adenoviral vectors that express immunostimulatory transgenes are currently being evaluated in clinic. Preclinical testing of these vectors has thus far been limited to immunodeficient xenograft tumor models since human...
6.
Harding T, Dickinson P, Roberts B, Yendluri S, Gonzalez-Edick M, LeCouteur R, et al.
Hum Gene Ther
. 2006 Sep;
17(8):807-20.
PMID: 16942441
In this study, recombinant AAV vectors pseudotyped with viral capsids derived from AAV serotypes 7 and 8 were evaluated for gene transfer in the murine striatum relative to vectors pseudotyped...
7.
Harding T, Lalani A, Roberts B, Yendluri S, Luan B, Koprivnikar K, et al.
Mol Ther
. 2006 Apr;
13(5):956-66.
PMID: 16580881
The presence of the blood-brain barrier complicates drug delivery in the development of therapeutic agents for the treatment of glioblastoma multiforme (GBM). The use of local gene transfer in the...
8.
Dishart K, Denby L, George S, Nicklin S, Yendluri S, Tuerk M, et al.
J Mol Cell Cardiol
. 2003 Jun;
35(7):739-48.
PMID: 12818564
Grafting of saphenous vein (SV) conduits into the arterial circulation triggers a number of adaptive pathological changes characterized by progressive medial thickening, neointima formation and accelerated atheroma. Previous studies have...